AbbVie Aktie News

Dividend Aristocrats rebounded in June and are now outperforming SPY YTD with a 9.61% return versus SPY's 6.91%. CAT leads 2026 performance at +76.98%, with 46 Aristocrats now ahead of SPY and 39 posting double-digit total returns. Recent dividend increases averaged 4.09%, slightly below the 2025 average, with 2026's average dividend growth rate at 3.97%.

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kg SKYRIZI becomes the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years of age and ol...

Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.

Stocks with above-average dividend yields often represent mature businesses with resilient earnings and disciplined management. A more strategic high-income equity solution can capture the benefits of dividend stocks while avoiding the pitfalls of overly simplistic approaches. FTSE Russell's flagship FTSE All-World Index includes large- and mid-cap stocks from nearly 50 developed and emerging m...

In this week's edition of InnovationRx, we look at AbbVie's new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get it in your inbox, subscribe here.

250 Women Entrepreneurs Have Been Selected to Join a Multi-Week Skill-Building, Mentorship, and Networking Program BOTOX® Cosmetic Will Award 20 Participants With $20,000 Grants Each to Help Take Their Business Dreams to the Next Level IRVINE, Calif., June 24, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2026 cohort of entrepreneurs selected to p...

Canada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey ® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar lines Boey® offers a differentiated treatment option for many people who are curious about facial injectables Results may be seen as early as ...

MAVIRET ® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children aged 3 years and older. The approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed, aiming to reduce delays in care and lower the risk o...